• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Regenerx Biopharmaceuticals Inc. (RGRX)

    -Other OTC
    0.46 Up 0.02(4.55%) 3:57PM EST
    ProfileGet Profile for:
    Regenerx Biopharmaceuticals Inc.
    15245 Shady Grove Road
    Suite 470
    Rockville, MD 20850
    United States - Map
    Phone: 301-208-9191
    Website: http://www.regenerx.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:2

    Business Summary 

    RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops and markets its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. It develops RGN-259, a topical eye drops that that has completed the Phase IIa exploratory clinical trials and for the regeneration of corneal tissues damaged by injury, disease, or other pathology; and RGN-352, an injectable formulation, which has completed Phase I clinical trials and is intended to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration. The company also develops RGN-137, a topical gel that is in Phase II clinical trials and intended for the treatment of epidermolysis bullosa, pressure ulcers, and venous stasis ulcers. In addition, it seeks to identify and evaluate Tß4 peptide fragments and derivatives for use as components in cosmeceutical and consumer products. The company has a strategic partnership with Defiante Farmaceutica S.A. for the development and marketing of RGN-137 and RGN-352 for specified indications in Europe and other countries. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regenerx Biopharmaceuticals Inc.

    Key Executives 
     PayExercised
    Dr. Allan L. Goldstein Ph.D., 78
    Founder, Chairman, Chief Scientific Advisor and Chairman of Medical & Scientific Advisory Board
    62.00K0.00
    Mr. J. J. Finkelstein , 64
    Chief Exec. Officer, Pres and Director
    114.00K0.00
    Mr. Alan Klein MBA,
    Chief Bus. Officer
    N/AN/A
    Mr. Richard J. Hindin , 73
    Sec.
    N/AN/A
    Dr. Nabila A. Turjman Ph.D.,
    Exec. Director of Regulatory Affairs
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders